1. Home
  2. DPC vs BLLN Comparison

DPC vs BLLN Comparison

Compare DPC & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DPC Holdings PLC Ordinary Shares

DPC

DPC Holdings PLC Ordinary Shares

N/A

Current Price

$51.35

Market Cap

6.8B

Sector

N/A

ML Signal

N/A

Logo BillionToOne Inc.

BLLN

BillionToOne Inc.

HOLD

Current Price

$96.79

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DPC
BLLN
Founded
N/A
2016
Country
United States
Employees
N/A
713
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
5.8B
IPO Year
2026
N/A

Fundamental Metrics

Financial Performance
Metric
DPC
BLLN
Price
$51.35
$96.79
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$126.71
AVG Volume (30 Days)
998.6K
784.7K
Earning Date
N/A
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$46.29
Revenue Next Year
N/A
$30.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$42.50
$61.96
52 Week High
$57.25
$150.44

Technical Indicators

Market Signals
Indicator
DPC
BLLN
Relative Strength Index (RSI) 53.31 36.77
Support Level $43.47 $73.46
Resistance Level N/A $108.50
Average True Range (ATR) 3.81 8.11
MACD 0.80 -5.39
Stochastic Oscillator 61.08 14.33

Price Performance

Historical Comparison
DPC
BLLN

About DPC DPC Holdings PLC Ordinary Shares

DPC Holdings PLC is a manufacturer of complex precision cast components for aerospace engines and industrial gas turbines. It produces metal components and specialized products for aerospace and industrial applications and operates manufacturing facilities across multiple locations globally.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: